touchONCOLOGY spoke to Dr Lizza Hendriks (Maastricht University, The Netherlands) to discuss her presentation at the European Lung Cancer Congress 2022, providing an update on the use of immunotherapy for the treatment for non-oncogene addicted non-small cell lung cancer with brain metastases.
Questions
- Could you give us a brief overview of current treatments for non-oncogene addicted non-small cell lung cancer (NSCLC) with brain metastases? 00:17-00:48
- What clinical evidence supports the use of immunotherapy in this setting? 00:48-01:44
- What factors should influence the decision to use immunotherapy? 01:44-02:21
- What unanswered questions remain? 02:21-03:08
Speaker Disclosure: Lizza Hendriks discloses grant/research support from AstraZeneca, Roche, Boehringer and Takeda. She is a member of the Advisory Board for: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Novartis, Amgen and Janssen. She is a speaker’s bureau participant with: MSD and Lilly. Other financial or material support includes: travel/conference reimbursement from Roche Genentech (self); mentorship program with key opinion leaders funded by AstraZeneca; fees for educational webinars from: Benecke, Medtalks, VJOncology (self) and high5oncology (institution); interview sessions funded by Roche Genentech, Bayer and Lilly (institution); local principle investigator of clinical trials: AstraZeneca, Novartis, BMS, MSD /Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals and Mirati.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Congress 2022
